M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.
Angie M. Jarrad,Chee Wei Ang,Anjan Debnath,Hye Jee Hahn,Kyra Woods,Lendl Tan,Melissa Sykes,Amy J. Jones,Ruby Pelingon,Mark S. Butler,Vicky M. Avery,Nicholas P. West,Tomislav Karoli,Mark A. T. Blaskovich,Mark E. Cooper +14 more
TL;DR: It is shown that pretomanid also possesses potent activity against Giardia lamblia and Entamoeba histolytica, thus expanding the therapeutic potential of nitroimidazooxazines and suggesting that promising subclasses of bicyclic nitroIMidazoles containing different core architectures have potential for further development.
Journal ArticleDOI
Breeding crops for drought-affected environments and improved climate resilience
Mark E. Cooper,Carlos D. Messina +1 more
TL;DR: In this paper , the authors apply the framework of the "breeder's equation", which is used to predict the response to selection for a breeding program cycle, to successfully breed crops with improved levels of drought resistance, where the target population of environments (TPEs) is a spatially and temporally heterogeneous mixture of drought-affected and favorable (water-sufficient) environments.
Journal ArticleDOI
Norbornane-based cationic antimicrobial peptidomimetics targeting the bacterial membrane.
Shane M. Hickey,Trent D. Ashton,Gareth Boer,Christie A. Bader,Michael Thomas,Alysha G. Elliott,Carsten Schmuck,Heidi Y. Yu,Jian Li,Roger L. Nation,Mark E. Cooper,Sally E. Plush,Douglas A. Brooks,Frederick M. Pfeffer +13 more
TL;DR: Molecular modelling indicates rapid aggregation of this class of antibacterial agent prior to membrane association and insertion and confocal microscopy studies indicate that the primary site of interaction for this family of compounds is the bacterial membrane.
Journal ArticleDOI
Agents in development for the treatment of diabetic nephropathy.
TL;DR: The molecular mechanisms of diabetic nephropathy are discussed and new therapies, including those targeting the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS) generation, are likely to feature in future treatment regimens.
Journal ArticleDOI
Synthesis of N-acylaziridines from β-amido selenides
TL;DR: The low temperature oxidation of β-amido selenides with MCPBA affords the corresponding β-AMIDI selenones in situ treatment of the selenone with KOtBu gives Nacylaziridines in good yield as mentioned in this paper.